Cargando…

Combination Therapies with PRRT

Peptide receptor radionuclide therapy (PRRT) is a successful targeted radionuclide therapy in neuroendocrine tumors (NETs). However, complete responses remain elusive. Combined treatments anticipate synergistic effects and thus better responses by combining ionizing radiation with other anti-tumor t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yordanova, Anna, Ahmadzadehfar, Hojjat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538931/ https://www.ncbi.nlm.nih.gov/pubmed/34681229 http://dx.doi.org/10.3390/ph14101005

Ejemplares similares

Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors
por: Yordanova, Anna, et al.
Publicado: (2020)

[(18)F]Fluorodeoxyglucose Positron Emission Tomography Reveals a Complete Remission of Refractory Metastatic Melanoma after Therapy with Ipilimumab
por: Yordanova, Anna, et al.
Publicado: (2017)

Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements
por: Merola, Elettra, et al.
Publicado: (2023)

Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
por: Awang, Zool Hilmi, et al.
Publicado: (2018)

The PRRT2 knockout mouse recapitulates the neurological diseases associated with PRRT2 mutations
por: Michetti, Caterina, et al.
Publicado: (2017)

Theranostics in nuclear medicine practice
por: Yordanova, Anna, et al.
Publicado: (2017)

Therapeutic response and side effects of repeated radioligand therapy with (177)Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2016)

Radioligand therapy of metastatic prostate cancer using (177)Lu-PSMA-617 after radiation exposure to (223)Ra-dichloride
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2017)

PRRT: identikit of the perfect patient
por: Albertelli, M., et al.
Publicado: (2020)

Functional study and pathogenicity classification of PRRT2 missense variants in PRRT2‐related disorders
por: Zhao, Shao‐Yun, et al.
Publicado: (2019)

Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [(177)Lu]Lu-PSMA-617 radioligand therapy
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2017)

(177)Lu-DOTATATE and (177)Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment
por: Assadi, Majid, et al.
Publicado: (2019)

PRRT2, a network stability gene
por: Michetti, Caterina, et al.
Publicado: (2017)

Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review
por: Camus, Baptiste, et al.
Publicado: (2021)

Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies
por: Bison, Sander M., et al.
Publicado: (2015)

First Results and Experience with PRRT in South Africa
por: Vorster, Mariza, et al.
Publicado: (2018)

New Insights in PRRT: Lessons From 2021
por: Puliani, Giulia, et al.
Publicado: (2022)

It is time to move forward into the era of Theranostics
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2018)

Galloping tongue syndrome in a PRRT2 mutation carrier
por: Vilas, Dolores, et al.
Publicado: (2019)

An Emerging Role of PRRT2 in Regulating Growth Cone Morphology
por: Savino, Elisa, et al.
Publicado: (2021)

Theranostic Advances in Breast Cancer in Nuclear Medicine
por: Vahidfar, Nasim, et al.
Publicado: (2021)

PSMA Theranostics: Current Status and Future Directions
por: Rahbar, Kambiz, et al.
Publicado: (2018)

Diagnostic accuracy of [(99m)Tc]Tc-Sestamibi in the assessment of thyroid nodules
por: Yordanova, Anna, et al.
Publicado: (2017)

Neoadjuvant PRRT for advanced pNEN: an unusual highlander
por: Zanata, Isabella, et al.
Publicado: (2021)

PRRT2 Mutant Leads to Dysfunction of Glutamate Signaling
por: Li, Ming, et al.
Publicado: (2015)

Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate
por: Bergsma, Hendrik, et al.
Publicado: (2016)

Paroxysmal Dyskinesias in a PRRT2 Mutation Carrier
por: Marano, Massimo, et al.
Publicado: (2018)

Long-term prognostic factors for PRRT in neuroendocrine tumors
por: Trautwein, Nils Florian, et al.
Publicado: (2023)

A Review of Nuclear Medicine Approaches in the Diagnosis and the Treatment of Gynecological Malignancies
por: Vahidfar, Nasim, et al.
Publicado: (2022)

Systemic Therapy of Neuroendocrine Neoplasia: Single Center Experience from a Cohort of 110 Consecutive Cases
por: Mayer, Karin, et al.
Publicado: (2020)

Supportive Management of Patients with Advanced Pheochromocytomas and Paragangliomas Receiving PRRT
por: Tsang, Erica S., et al.
Publicado: (2021)

Abstracts of Poster Presentations (NET/ PRRT/ Molecular Imaging/ Radiopharmacy)
Publicado: (2011)

Identification of PRRT2 as the causative gene of paroxysmal kinesigenic dyskinesias
por: Wang, Jun-Ling, et al.
Publicado: (2011)

Paroxysmal hypnogenic dyskinesia is associated with mutations in the PRRT2 gene
por: Liu, Xiao-Rong, et al.
Publicado: (2016)

PRRT2 Mutations Are Related to Febrile Seizures in Epileptic Patients
por: He, Zheng-Wen, et al.
Publicado: (2014)

PRRT2 mutations lead to neuronal dysfunction and neurodevelopmental defects
por: Liu, Yo-Tsen, et al.
Publicado: (2016)

PRRT of neuroendocrine tumors: individualized dosimetry or fixed dose scheme?
por: Haug, Alexander R.
Publicado: (2020)

Challenges in Von Hippel–Lindau’s disease: PRRT in patients on hemodialysis
por: Ayub, N, et al.
Publicado: (2022)

Post-PRRT scans: which scans to make and what to look for
por: Aalbersberg, Else A., et al.
Publicado: (2022)

The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
por: Harris, Philip E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qc9f5cgs7q3unq5fk0pead7972